Everything below concerns melanocortin signalling. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-07-26. Numbers and descriptions here follow the published literature rather than marketing material.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
In 2023, it was the 246th most commonly prescribed medication in the United States, with more than 1 million prescriptions. It is available as a generic medication. In 2023, the combination of dexamethasone with neomycin and polymyxin B was the 260th most commonly prescribed medication in the United States, with more than 1 million prescriptions; and the combination of dexamethasone with ciprofloxacin was the 283rd most commonly prescribed medication in the United States, with more than 700,000 prescriptions;
(2005), philanthropist, investor, activist, son of John Kluge '37 Alana Mayo (2006), president of Orion Pictures Liesel Pritzker Simmons (2006), former child actress, A Little Princess; granddaughter of businessman Abram Nicholas Pritzker, heiress to the Hyatt hotels fortune, philanthropist Wayne Ting (2006), CEO of Lime Marco Zappacosta (2007), co-founder and CEO of Thumbtack, son of Logitech founder Pierluigi Zappacosta Adam Pritzker (2008), co-founder of General Assembly, grandson of Jay Pritzker and member of the Pritzker family Jared Hecht (2009), co-founder of GroupMe Ariana Rockefeller (2009), fashion designer and great-great-granddaughter of John D. Rockefeller Zach Sims* (2012), co-founder of Codecademy Beverly Leon (2014), former midfielder of Sunderland A.F.C. Ladies, CEO of Local Civics Nicole LaPointe Jameson (2016), CEO of Evil Geniuses Korawad Chearavanont* (2017), Thai internet entrepreneur and grandson of Dhanin Chearavanont
Phlebotomies are carried out by phlebotomists – people trained to draw blood mostly from veins for clinical or medical testing, transfusions, donations, or research. Blood is collected primarily by performing venipunctures, or by using capillary blood sampling with fingersticks or a heel stick in infants for the collection of minute quantities of blood. The duties of a phlebotomist may include interpreting the tests requested, drawing blood into the correct tubes with the proper additives, accurately explaining the procedure to the person and preparing them accordingly, practicing the required forms of asepsis, practicing standard and universal precautions, restoring hemostasis of the puncture site, giving instructions on post-puncture care, affixing tubes with electronically printed labels, and delivering specimens to a laboratory. Some countries, states, or districts require that phlebotomists be licensed or registered. A therapeutic phlebotomy may be carried out in the treatment of some blood disorders (examples: hemochromatosis, polycythemia vera, porphyria cutanea tarda), and chronic hives (in research).
Sources: en.wikipedia.org
They noted a glycerin-bile-potato mixture grew bacilli that seemed less virulent and changed the course of their research to see if repeated subculturing would produce a strain that was attenuated enough to be considered for use as a vaccine. The BCG strain was isolated after subculturing 239 times during 13 years from a virulent strain on glycerine potato medium. The research continued throughout World War I until 1919 when the now avirulent bacilli were unable to cause tuberculosis disease in research animals. Calmette and Guerin transferred to the Paris Pasteur Institute in 1919. The BCG vaccine was first used in humans in 1921. Public acceptance was slow, and the Lübeck disaster, in particular, did much to harm it. Between 1929 and 1933 in Lübeck, 251 infants were vaccinated in the first 10 days of life; 173 developed tuberculosis and 72 died. It was subsequently discovered that the BCG administered there had been contaminated with a virulent strain that was being stored in the same incubator, which led to legal action against the vaccine's manufacturers. Dr. R. G. Ferguson, working at the Fort Qu'Appelle Sanatorium in Saskatchewan, was among the pioneers in developing the practice of vaccination against tuberculosis. In Canada, more than 600 children from residential schools were used as involuntary participants in BCG vaccine trials between 1933 and 1945. In 1928, the BCG vaccine was adopted by the Health Committee of the League of Nations (predecessor to the World Health Organization (WHO)).
=== Private industry === Many companies in the private sector have taken up use of open models for their flexibility, greater level of control, opportunities to fine-tune, and lower cost to use. AT&T, Thomson Reuters, Harvey, Nomura Holdings, Goldman Sachs, DoorDash and Accenture are among the companies that have moved at least some of their workload to open models. Some of the reported use cases include software development, specialized tasks such as document review and legal agentic tasks.
== F == Finegoldia magna Francisella tularensis (formerly Pasteurella tularensis) Fusobacterium Fusobacterium necrophorum Fusobacterium nucleatum (formerly Corynebacterium fusiforme) Frateuria aurantia (formerly Acetobacter aurantius)
Sources: en.wikipedia.org
Absolute waist circumference (>102 cm (40 in) in men and >88 cm (35 in) in women) Waist–hip ratio (the circumference of the waist divided by that of the hips of >0.9 for men and >0.85 for women) Waist-stature ratio (waist circumference divided by their height, >0.5 for adults under 40 and >0.6 for adults over 50) Sagittal Abdominal Diameter
== Advances in step-growth polymers == The driving force in designing new polymers is the prospect of replacing other materials of construction, especially metals, by using lightweight and heat-resistant polymers. The advantages of lightweight polymers include high strength and resistance to solvent and other chemicals, contributing to a variety of potential uses, such as electrical and engine parts on automotive and aircraft components, coatings on cookware, coatings and circuit boards for electronic and microelectronic devices, etc. Polymer chains based on aromatic rings are desirable due to high bond strengths and rigid polymer chains. High molecular weight and crosslinking are desirable for the same reason. Strong dipole-dipole interactions, hydrogen bonds, and crystallinity also improve heat resistance. To obtain desired mechanical strength, sufficiently high molecular weights are necessary, however, decreased solubility is a problem. One approach to solve this problem is to introduce of some flexibilizing linkages, such as isopropylidene, C=O, and SO2 into the rigid polymer chain by using an appropriate monomer or comonomer. Another approach involves the synthesis of reactive telechelic oligomers containing functional end-groups capable of reacting with each other; polymerization of the oligomer gives higher molecular weight, referred to as chain extension.
xv. ISBN 978-1-62683-043-1. Retrieved March 22, 2021. Siddiqi, Asif A. (2000). Challenge to Apollo: the Soviet Union and the space race, 1945–1974 (PDF). Washington, D.C.: National Aeronautics and Space Administration, NASA History Div. Retrieved February 10, 2026. Siddiqi, Asif A. (2003). Sputnik and the Soviet Space Challenge. Gainesville: University Press of Florida. ISBN 0-8130-2627-X. Siddiqi, Asif A. (2003). The Soviet Space Race with Apollo. Gainesville: University Press of Florida. ISBN 0-8130-2628-8. Stocker, Jeremy (2004). Britain and Ballistic Missile Defence, 1942–2002. London: Frank Case. pp. 12–24. ISBN 0-7146-5696-8. Swenson, Loyd S. Jr.; Grimwood, James M.; Alexander, Charles C. (1966). This New Ocean: A History of Project Mercury. NASA. ISBN 1-934941-87-5. Retrieved January 8, 2023. Turnhill, Reginald (2004). The Moonlandings: An Eyewitness Account. New York: Cambridge University Press. ISBN 0-521-81595-9. Pervushin, Anton (2011). 108 minutes which changed the world (in Russian). Эксмо. ISBN 978-5-699-48001-2.
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.